New pharma Azadyne raises £1.5m for autoimmune disease treatment
The Trinity College spin-off has completed a £1.5-million funding round for its autoimmune treatments.
28th March 2019
Latest news
NHS aims for one link worker per primary care network from July
The social prescription plan aims to bring about the major shift in perspective needed.
28th March 2019
AZ' Imfinzi to be funded for NHS use via CDF
AstraZeneca’s PD-L1 inhibitor Imfinzi will be made available on the NHS in England immediately for patients with locally advanced unresectable non-small-cell lung cancer.
28th March 2019
Number of prescription rises but cost falls again
Latest data from NHS Digital shows an increase in the number of prescription items dispensed in the community, but a drop in their cost to the NHS.
28th March 2019
Celgene resubmits MS drug, ozanimod, to FDA
A filing for ozanimod was initially rejected by the US regulator in February 2017.
27th March 2019
Phase III results move Aimmune’s peanut allergy drug closer to EU market
Aimmune to file peanut allergy drug in Europe based on Phase III data showing an improvement in peanut tolerance.
27th March 2019
Cancer immunotherapy alliance formed by CR UK, Lifearc and Ono Pharma Form
Cancer Research UK, LifeArc and Ono Pharmaceutical have formed a multi-million-pound drug discovery alliance.
27th March 2019
Novartis' MS drug gets FDA approval
The FDA has approved Novartis’ multiple sclerosis drug, Mayzent.
27th March 2019
NICE recommendation for Steglatro in type II diabetes
MSD's SGLT-2 inhibitor Steglatro will be available for some patients with type II diabetes on the NHS in England and Wales.
27th March 2019
Sanofi plans to ‘airlift’ flu vaccine into UK in no-deal event
Sanofi has said that it could potentially airlift its flu vaccine into the UK in the event of a no-deal Brexit.
26th March 2019
EU approves AZ' Forxiga for type I diabetes
The drug is the first oral medicine approved in Europe as an adjunct to insulin for adults with type I diabetes.
26th March 2019
Motif Bio raises £2.7 million via share placing
Motif Bio has announced that it has raised £2.7 million from a share placing, to provide additional working capital.
26th March 2019
Tiziana submits IND for Foralumab oral formulation in NASH
Tiziana has submitted an Investigational New Drug application for an oral formulation of Foralumab.
26th March 2019
Eisai, Biogen move Alzheimer’s treatment into Phase III
Eisai and Biogen's BAN2401 is to be put into Phase III trial for patients with early Alzheimer's disease.
26th March 2019
Thermo Fisher buys Brammer Bio for $1.7bn
Thermo Fisher is set to acquire Brammer Bio for approximately $1.7 billion.
26th March 2019
